Focused On-demand Library for Importin-13

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O94829

UPID:

IPO13_HUMAN

Alternative names:

Karyopherin-13; Ran-binding protein 13

Alternative UPACC:

O94829; D3DPY4; Q5T4X3; Q7LC04; Q96HS3; Q9H8N3; Q9UFR1

Background:

Importin-13, also known as Karyopherin-13 and Ran-binding protein 13, is a pivotal protein in nuclear protein import, acting as a nuclear transport receptor. It recognizes nuclear localization signals (NLS) in cargo substrates, facilitating their docking to the nuclear pore complex (NPC). This process involves an energy-dependent, Ran-mediated translocation through the NPC, with nuclear import directionality influenced by the differential distribution of GTP- and GDP-bound forms of Ran across the cytoplasm and nucleus. Importin-13 is crucial for the nuclear import of various proteins including UBC9 and PAX6, and also mediates the nuclear export of eIF-1A.

Therapeutic significance:

Understanding the role of Importin-13 could open doors to potential therapeutic strategies.